Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: Increasing prevalence and risk factors

Annals of Oncology

Volumn 26, Issue 10, 2015, Pages 2133-2140

  Sprauten, M ^a   Haugnes, H S ^b,c   Brydoy M ^d   Kiserud, C ^a   Tandstad, T ^e   Bjoro T ^a,f   Bjerner, J ^g   Cvancarova, M ^a   Fossa S D ^a   Oldenburg, Jan ^a,h  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

^g Furst Medical Laboratory   (Norway)

^h AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Fatigue; Hypogonadism; Physical activity; Survivorship; Testicular cancer; Testosterone

Indexed keywords

LUTEINIZING HORMONE; TESTOSTERONE;

ADULT; AGED; ANEMIA; ANXIETY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVOR; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; EARLY DIAGNOSIS; FATIGUE; FOLLOW UP; GROUPS BY AGE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HYPOGONADISM; LIFESTYLE MODIFICATION; LONG TERM CARE; LONGITUDINAL STUDY; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MUSCLE MASS; MUSCLE STRENGTH; NEUROPATHY; NEUROTOXICITY; OSTEOPOROSIS; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; RISK REDUCTION; TESTIS CANCER; TESTOSTERONE BLOOD LEVEL; ADOLESCENT; BLOOD; CHRONIC DISEASE; COMPLICATION; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; NORWAY; PATHOPHYSIOLOGY; PROGNOSIS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; SURVIVOR; TESTICULAR NEOPLASMS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANXIETY; CHRONIC DISEASE; COMORBIDITY; DEPRESSION; FATIGUE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; NORWAY; PREVALENCE; PROGNOSIS; RISK FACTORS; SURVIVORS; TESTICULAR NEOPLASMS; TESTOSTERONE; YOUNG ADULT;

EID: 84943741881     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv328     Document Type: Article

References (30)

1. Bower JE. Cancer-related fatigue-mechanisms, risk factors, and treatments. Nat Rev Clin Oncol 2014; 11: 597-609.
2. Cancer in Norway 2012. Cancer Registry of Norway 2014; http://www. kreftregisteret.no/en/.
3. Oldenburg J, Fosså SD, Nuver J et al. Testicular seminoma and non-seminoma:ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24: vi125-vi132.
4. Haugnes HS, Bosl GJ, Boer H et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol 2012; 30:3752-3763.
5. Sprauten M, Brydøy M, Haugnes HS et al. Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a populationbased sample of long-term testicular cancer survivors. J Clin Oncol 2014; 32:571-578.
6. Huddart RA, Norman A, Moynihan C et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 2005; 93: 200-207.
7. Dahl AA, Haaland CF, Mykletun A et al. Study of anxiety disorder and depression in long-term survivors of testicular cancer. J Clin Oncol 2005; 23: 2389-2395.
8. Eberhard J, Ståhl O, Cohn-Cedermark G et al. Sexual function in men treated for testicular cancer. J Sex Med 2009; 6: 1979-1989.
9. Dahl AA, Bremnes R, Dahl O et al. Is the sexual function compromised in longterm testicular cancer survivors? Eur Urol 2007; 52: 1438-1447.
10. Haugnes HS, Wethal T, Aass N et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010; 28: 4649-4657.
11. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992; 117:807-811.
12. Greenfield DM, Walters SJ, Coleman RE et al. Quality of life, self-esteem, fatigue, and sexual function in young men after cancer. Cancer 2010; 116: 1592-1601.
13. Fukuda K, Straus SE, Hickie I et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994; 121:953-959.
14. Fosså SD, Dahl AA, Loge JH. Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol 2003; 21: 1249-1254.
15. Loge JH, Ekeberg O, Kaasa S. Fatigue in the general Norwegian population:normative data and associations. J Psychosom Res 1998; 45: 53-65.
16. Sprauten M, Darrah TH, Peterson DR et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer. J Clin Oncol 2012; 30: 300-307.
17. Oldenburg J, Fosså SD, Dahl AA. Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res 2006; 15: 791-800.
18. Chalder T, Berelowitz G, Pawlikowska T et al. Development of a fatigue scale. J Psychosom Res 1993; 37: 147-153.
19. Minton O, Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol 2009; 20: 17-25.
20. Pawlikowska T, Chalder T, Hirsch SR et al. Population based study of fatigue and psychological distress. BMJ 1994; 308: 763-766.
21. Bjelland I, Dahl AA, Haug TT et al. The validity of the hospital anxiety and depression scale: an updated literature review. J Psychosom Res 2002; 52:69-77.
22. Thorsen L, Nystad W, Dahl O et al. The level of physical activity in long-term survivors of testicular cancer. Eur J Cancer 2003; 39: 1216-1221.
23. Bjerner J, Biernat D, Fosså SD et al. Reference intervals for serum testosterone, SHBG, LH and FSH in males from the NORIP project. Scand J Clin Lab Invest 2009; 69: 873-879.
24. Collett D. Modelling Survival Data in Medical Research, 3rd edition, Boca Raton, FL: Taylor & Francis 2014.
25. Oerlemans S, Mols F, Issa DE et al. A high level of fatigue among long-term survivors of non-Hodgkin's lymphoma: results from the longitudinal populationbased PROFILES registry in the south of the Netherlands. Haematologica 2013; 98: 479-486.
26. Daniels L, Oerlemans S, Krol A et al. Persisting fatigue in Hodgkin lymphoma survivors: a systematic review. Ann Hematol 2013; 92: 1023-1032.
27. Bower JE, Bak K, Berger A et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation. J Clin Oncol 2014; 32: 1840-1850.
28. Ganz PA, Bower JE. Cancer related fatigue: a focus on breast cancer and Hodgkin's disease survivors. Acta Oncol 2007; 46: 474-479.
29. Snyder PJ, Peachey H, Berlin JA et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocr Metab 2000; 85: 2670-2677.
30. Hansen SW, Helweg-Larsen S, Trojaborg W. Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J Clin Oncol 1989; 7: 1457-1461.